Financial Contrast: iBio (NYSE:IBIO) vs. Nemus Bioscience (OTCMKTS:NMUS)

Nemus Bioscience (OTCMKTS:NMUS) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Volatility and Risk

Nemus Bioscience has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Nemus Bioscience and iBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemus Bioscience	0	0	0	0	0.00
iBio	0	0	1	0	3.00

iBio has a consensus target price of $5.00, indicating a potential upside of 658.73%. Given iBio’s stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Nemus Bioscience.

Valuation & Earnings

This table compares Nemus Bioscience and iBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemus Bioscience	N/A	N/A	-$19.19 million	N/A	N/A
iBio	$375,000.00	29.03	-$24.91 million	N/A	N/A

Nemus Bioscience has higher earnings, but lower revenue than iBio.

Profitability

This table compares Nemus Bioscience and iBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemus Bioscience	N/A	N/A	-924.42%
iBio	N/A	-73.15%	-45.51%

Insider and Institutional Ownership

7.9% of iBio shares are held by institutional investors. 2.7% of Nemus Bioscience shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

iBio beats Nemus Bioscience on 7 of the 10 factors compared between the two stocks.

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.